Genomic Alteration Detection
We offer tests for gene mutation detection test and fusion detections.
EGFR mutation detection test
ALK, RET, and ROS1 fusion detection tests
Lung Cancer
Lung cancer is the leading cause for cancer-related death.
Non-small cell lung cancer (NSCLC) accounts for 85% lung cancer cases
Among NSCLC patients studies, many patients contain genomic alterations in tumor cells, including mutations (point mutations, insertions and deletions) and in-frame gene-fusions due to chromosomal translocation
Various drugs have been approved for targeted therapy against these genomic alterations for lung cancer
Companion diagnostics used to identify the genomic alterations is required before these drugs are used for the therapy benefit of patients.
EGFR Mutations
EGFR (epidermal growth factor receptor) mutations are widely studied among NSCLC patients. With 10 to 20% mutations in the Caucasian population and up to 50% in Asian, EGFR mutations are well characterized, including the classical mutations such as L858, Exon 19 deletions, and Exon 20 insertions and non-classical mutations including C719, L861, and drug resistance mutations C790M and C797S.
Gene Fusions
Gene fusions in NSCLC include the most common ones, such as ALK (Anaplastic lymphoma kinase), ROS1 (ROS proto-oncogene 1) and RET (rearranged during transfection proto-oncogene) fusions and less common fusion genes such as NTRK )(neurotrophic tyrosine receptor kinase), NRG1 (neuregulin 1), FGFR (fibroblast growth factor receptor), MET (mesenchymal-epithelial transition factor), EGFR, and BRAF (v-RAF murine sarcoma viral oncogene homolog B1) fusions.
